

Speaker Biography



Prof. Xavier Mariette, MD, PhD

Head of the Rheumatology Department

Bicêtre Hospital, Paris-Saclay University

Prof. Xavier Mariette, MD, PhD, has served as the Head of the Rheumatology Department of Bicêtre Hospital, Paris-Saclay University since 1999, a role he took following 10 years of practice of clinical immunology in Paris-Diderot University.

Prof. Mariette has initiated a number of clinical research studies on long-term tolerance of biotherapies in rheumatoid arthritis and autoimmune diseases: RATIO (Research Axed on Tolerance of Biotherapy) for anti-TNF, AIR (Autoimmunity and Rituximab) and ORA (Orencia and Rheumatoid arthritis).

He initiated clinical trials in Sjögren's syndrome with infliximab, hydroxychloroquine, rituximab and belimumab. He coordinated different consortia for setting-up activity scores for evaluation of the disease in patients with Sjögren's syndrome: ESSDAI, ESSPRI and STAR.

Recently, he worked on rheumatic adverse effects observed with immune checkpoint therapy of cancer and he initiated clinical trials on immune modulators for the treatment of severe COVID-19, for example the first trial having demonstrated the efficacy of tocilizumab.

Pr Mariette is involved in basic research, leading a group working on pathogeny of Sjögren's syndrome. He made the first emphasis on the role of the cytokine BAFF in pathogeny of this disease, which led to the development of promising therapeutic approaches for inhibiting it.

In basic research, his group also works on relationships between innate immunity and B-cell activation in autoimmunity, macrophages in rheumatoid arthritis and the relationships between autoimmunity and lymphoma.

Pr Mariette has been the President of the Scientific Committee of the EULAR meeting in Berlin in 2012 and has been from 2016 to 2020 the Chair of the EULAR standing committee on investigative rheumatology.

Pr Mariette is co-author of more than 650 publications referenced in PubMed with an H-index of 98 (Web of Science).